NextPoint Therapeutics, Inc.

👥 38 employees💰 Last funded Jan 2023
Biotechnology🌐 nextpointtx.com
Website LinkedIn
NextPoint is launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint inhibitor. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed modality, so that we can deliver first-in-class therapies to a broad range of cancer patients with B7-H7 upregulation including those who do not benefit from currently approved therapies such as PD-1/L1 inhibitors.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2022–2023 · investors recorded per year
2022120232
Recent (last 2y)Earlier
Frequently asked questions
Who invested in NextPoint Therapeutics, Inc.?
NextPoint Therapeutics, Inc. has 3 investors on record on gritt.io.
When did NextPoint Therapeutics, Inc. last raise funding?
The most recent investment in NextPoint Therapeutics, Inc. recorded on gritt.io was in January 2023.
What industry is NextPoint Therapeutics, Inc. in?
NextPoint Therapeutics, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.